Diabetes Introduction Treatments Complications Statistics Clinical Trials
NDEP Awareness and Prevention Series Resources Order About NDIC Informacion en Espanol
dots
A to Z list of Diabetes Topics and Titles Easy-to-Read Publications Spanish-language Publications Awareness and Prevention Series
Email to a friend  Email to a friend icon
Print this page    Print this page icon
 Home : Clinical Trials, Guidelines, and Reports : Diabetes Control and Complications Trial : Impact of Long-Term Complications of IDDM
 

Impact of Long-Term Complications of IDDM

Click here to start slide show

Table of Contents

  1. Impact of Long-Term Complications of IDDM
  2. The Glucose Hypothesis
  3. Clinical Trials of Intensive Therapy and Retinopathy
  4. Study Questions: Primary Prevention
  5. Study Questions: Secondary Intervention
  6. Structure
  7. Study Plan
  8. Key Study Features
  9. Clinical Centers
  10. Eligibility Criteria
  11. Baseline Characteristics
  12. Conventional Therapy
  13. Intensive Therapy Goals
  14. Intensive Therapy Methods
  15. Completeness of Follow Up
  16. Distribution of Study Time
  17. Patient-Years in Study
  18. Adherence to Protocol
  19. Adherence to Assigned Treatment
  20. Separation of HbA1c: Combined Cohort
  21. Separation of HbA1c: Adolescents
  22. Separation of BG Profiles: Combined Cohort
  23. Separation of BG Profiles: Adolescents
  24. Distribution of HbA1c
  25. Percent of Subjects in Mean HbA1c Categories
  26. Measures of Ophthalmic Outcome
  27. Retinopathy Scale
  28. Analytic Methods
  29. Analytic Methods, Continued
  30. Risk Reduction With Intensive Therapy
  31. Cumulative Incidence of Greater Than Or Equal To 1 Microaneurysm
  32. Cumulative Incidence of Greater Than Or Equal To 3-Step Change
  33. Point Prevalence of Greater Than Or Equal To 3-Step Change
  34. Cumulative Incidence of Greater Than Or Equal To 3-Step Sustained Change
  35. Cumulative Incidence of Greater Than Or Equal To 3-Step Change
  36. Point Prevalence of Greater Than Or Equal To 3-Step Progression
  37. Cumulative Incidence of Greater Than Or Equal To 3-Step Sustained Progression
  38. Severe Ophthalmic Events: Primary Prevention
  39. Severe Ophthalmic Events: Secondary Intervention
  40. Risk Reduction With Intensive Therapy
  41. Subgroup Analyses for Retinopathy
  42. Risk for Severe Nonproliferative Retinopathy Associated With 3-Step Change
  43. Summary of Risk Reduction With Intensive Therapy
  44. Association Between Mean HbA1c and 3-Step Progression: Intensive Therapy
  45. Measures of Nephropathy
  46. Analytic Outcomes for Nephropathy
  47. Risk Reduction With Intensive Therapy
  48. Cumulative Incidence of Microalbuminuria and Albuminuria: Primary Prevention
  49. Cumulative Incidence of Sustained Microalbuminuria
  50. Cumulative Incidence of Microalbuminuria and Albuminuria: Combined Cohorts
  51. Cumulative Incidence of Microalbuminuria and Albuminuria: Secondary Intervention
  52. Measures of Neuropathy
  53. Definition of Clinical Neuropathy
  54. Prevalence of Clinical Neuropathy
  55. Prevalence of Abnormal Neurologic Results at 5 Years
  56. Measures of Macrovascular Disease and Risk Factors
  57. Analytic Definitions of Macrovascular Events
  58. Major Macrovascular Events
  59. Major Macrovascular Events, Continued
  60. Incidence of Cardiac Risk Factors
  61. Goals of Neuropsychological and Quality of Life Analyses
  62. Neurobehavioral, Psychological and Quality of Life Measures
  63. Analytic Definition of Neurobehavioral and Psychological Events
  64. Neurobehavioral Events
  65. Cumulative Incidence of Psychologic Events
  66. Adverse Events
  67. Adverse Events: Severe Hypoglycemia
  68. Severe Hypoglycemia
  69. Association Between Severe Hypoglycemia and Most Recent HbA1c: Intensive Therapy
  70. DCCT Clinics
  71. DCCT Clinics, Continued
  72. DCCT Clinics, Continued
  73. Summary
  74. Summary, Continued
  75. Summary, Continued
  76. Summary, Continued
  77. Summary, Continued
  78. Summary, Continued
  79. Summary, Continued
  80. DCCT Resources for Intensive Therapy
  81. Recommendations
  82. Recommendations, Continued
  83. Recommendations, Continued
  84. Recommendations, Continued
  85. Recommendations, Continued
  86. Recommendations, Continued
  87. Conclusion
[Top]
  

dot

Diabetes Home | Diabetes A to Z | Introduction | Treatments | Complications | Statistics | Clinical Trials | NDEP | Awareness and Prevention | Additional Resources | Order Publications | About Us | Información en Español

Contact Us | Health Information

The NDIC is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

National Diabetes Information Clearinghouse
1 Information Way
Bethesda, MD 20892–3560
Phone: 1–800–860–8747
Fax: 703–738–4929
Email: ndic@info.niddk.nih.gov
Privacy | Disclaimer | Accessibility
H H S logo - link to U. S. Department of Health and Human Services
NIH logo - link to the National Institute of Health
NIDDK logo - link to the National Institute of Diabetes and Digestive and Kidney Diseases